Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

228 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Goetz MP, et al. Among authors: sledge gw jr. Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06029-y. Online ahead of print. Breast Cancer Res Treat. 2021. PMID: 33392835
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
Sledge GW Jr, Frenzel M. Sledge GW Jr, et al. JAMA Oncol. 2020 Jul 1;6(7):1122-1123. doi: 10.1001/jamaoncol.2020.1518. JAMA Oncol. 2020. PMID: 32463426 No abstract available.
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA Jr, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW Jr, Cella D. Wagner LI, et al. Among authors: sledge gw jr. J Clin Oncol. 2020 Jun 10;38(17):1875-1886. doi: 10.1200/JCO.19.01866. Epub 2020 Apr 9. J Clin Oncol. 2020. PMID: 32271671
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW Jr. Kaufman PA, et al. Among authors: sledge gw jr. Oncologist. 2020 Feb;25(2):e243-e251. doi: 10.1634/theoncologist.2019-0551. Epub 2019 Oct 24. Oncologist. 2020. PMID: 32043763 Free PMC article.
Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.
Ling AY, Kurian AW, Caswell-Jin JL, Sledge GW Jr, Shah NH, Tamang SR. Ling AY, et al. Among authors: sledge gw jr. JAMIA Open. 2019 Sep 18;2(4):528-537. doi: 10.1093/jamiaopen/ooz040. eCollection 2019 Dec. JAMIA Open. 2019. PMID: 32025650 Free PMC article.
Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.
von Itzstein MS, Railey E, Smith ML, White CB, Sledge GW Jr, Howell JR, Lawton W, Marinucci DM, Unni N, Gerber DE. von Itzstein MS, et al. Among authors: sledge gw jr. Cancer. 2020 Apr 15;126(8):1605-1613. doi: 10.1002/cncr.32730. Epub 2020 Jan 22. Cancer. 2020. PMID: 31967687 Free PMC article.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr. Sparano JA, et al. Among authors: sledge gw jr. JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794. JAMA Oncol. 2020. PMID: 31566680 Free PMC article. Clinical Trial.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. Sledge GW Jr, et al. JAMA Oncol. 2019 Sep 29;6(1):116-24. doi: 10.1001/jamaoncol.2019.4782. Online ahead of print. JAMA Oncol. 2019. PMID: 31563959 Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Sparano JA, et al. Among authors: sledge gw jr. N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3. N Engl J Med. 2019. PMID: 31157962 Free PMC article. Clinical Trial.
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.
Di Leo A, O'Shaughnessy J, Sledge GW Jr, Martin M, Lin Y, Frenzel M, Hardebeck MC, Smith IC, Llombart-Cussac A, Goetz MP, Johnston S. Di Leo A, et al. Among authors: sledge gw jr. NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30588487 Free PMC article.
228 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback